MED Stock Chart & Stats
$180.00
$0.00(0.00%)
At close: 4:00 PM EDT
$180.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$175.00 - $370.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$2.55B
Enterprise Value-$23.04M
Total Cash (Recent Filing)$172.53M
Total Debt (Recent Filing)$20.68M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Feb 23, 2027EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding11,182,597
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$222.66Price Target Upside23.70% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-21.53
Revenue Forecast (FY)$5.39B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe debt-free balance sheet and substantial cash reserve provide financial flexibility while Medifast restructures its cost base and invests in growth initiatives. This liquidity reduces near-term financing pressure and gives management capacity to support the Trilogy transition despite current operating losses.
Improving Coach ProductivityRepeated year-over-year productivity gains indicate that the coach network is generating more revenue per active participant, partially offsetting its smaller size. If sustained, higher productivity can improve customer economics, strengthen coach engagement, and support eventual revenue stabilization.
Metabolic Health Product ExpansionThe move from traditional weight management toward a broader metabolic health system expands the company’s product positioning and customer conversation. New formulations, training, and multi-phase programs could improve differentiation and retention if adoption continues across the coach network.
Bears Say
Sharp Revenue ContractionThe prolonged revenue decline shows that Medifast has not yet stabilized demand after the business contracted substantially. A smaller sales base reduces operating leverage, limits reinvestment capacity, and makes a durable return to profitability dependent on reversing the underlying customer and coach trends.
Shrinking Coach NetworkThe sharp reduction in active earning coaches weakens Medifast’s primary customer-acquisition and support channel. Management expects the decline to continue in the near term, creating a structural risk that productivity gains will be insufficient to offset fewer coaches and constrain future revenue growth.
Losses And Weak Cash GenerationPersistent operating and net losses, combined with slightly negative free cash flow, show that the current revenue base is not covering the company’s cost structure. Continued losses can erode equity and cash reserves over time, increasing execution pressure even though leverage remains low.
Medifast News
MED FAQ
What was Medifast Inc’s price range in the past 12 months?
Medifast Inc lowest stock price was $175.00 and its highest was $370.00 in the past 12 months.
What is Medifast Inc’s market cap?
Medifast Inc’s market cap is $2.55B.
When is Medifast Inc’s upcoming earnings report date?
Medifast Inc’s upcoming earnings report date is Feb 23, 2027 which is in 115 days.
How were Medifast Inc’s earnings last quarter?
Medifast Inc released its earnings results on Oct 26, 2026. The company reported -$3.569 earnings per share for the quarter, beating the consensus estimate of -$6.575 by $3.006.
Is Medifast Inc overvalued?
According to Wall Street analysts Medifast Inc’s price is currently Undervalued.
Does Medifast Inc pay dividends?
Medifast Inc does not currently pay dividends.
What is Medifast Inc’s EPS estimate?
Medifast Inc’s EPS estimate is 0.19.
How many shares outstanding does Medifast Inc have?
Medifast Inc has 11,182,597 shares outstanding.
What happened to Medifast Inc’s price movement after its last earnings report?
Medifast Inc reported an EPS of -$3.569 in its last earnings report, beating expectations of -$6.575. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medifast Inc?
Currently, no hedge funds are holding shares in MX:MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$222.66 (23.70% Upside)
$222.66 (23.70% Upside)
Blogger Sentiment
Bullish
MX:MED Sentiment 71%
Sector Average 58%
Sector Average 58%
Insider Transactions
Bought Shares
Worth $23.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.08%
12-Months-Change
Fundamentals
Return on Equity
-21.13%
Trailing 12-Months
Asset Growth
-10.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medifast Inc
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call was cautiously positive. Management highlighted successful execution of the Trilogy 3.0 launch, improving coach productivity, strong product adoption, a debt-free balance sheet, cost realignment, and a stated path to fourth-quarter profitability. However, these positives were offset by a 19.4% revenue decline, a substantial reduction in active earning coaches, continued GLP-1-related pressure on the traditional weight loss category, and significantly larger GAAP operating and net losses. The outlook is constructive but remains dependent on improving coach growth while sustaining productivity gains.View all MX:MED earnings summariesMED Stock 12 Month Forecast
Average Price Target
$222.66
▲(23.70% Upside)